Mark Socinski, MD

Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to complement or, in some cases, substitute for tissue-based testing.

Current NCCN guidelines for early-stage NSCLC recommend testing for key biomarkers to guide decisions regarding adjuvant targeted therapy or immunotherapy.

Comprehensive biomarker testing at the time of early NSCLC diagnosis is critical because it ensures that clinicians identify actionable molecular alterations before definitive treatment plans are set.

Comprehensive biomarker testing in early-stage NSCLC requires coordination across multiple specialties, including thoracic surgery, medical oncology, pathology, pulmonology, and radiology.

Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.

Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.

Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.

Mark Socinski, MD and Joshua Sabari, MD review the key efficacy data from the KRYSTAL 1b cohort and discusses strategies for managing adverse events seen with adagrasib.

Drs Socinski and Sabari discuss the emergence of the KRAS12C mutation, specifically in patients with CNS metastases and how this factors into their treatment decision.

Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.

Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.

The PACIFIC study included patients with good performance status and unresectable, stage III NSCLC who did not progress after definitive platinum-based chemotherapy with concurrent radiation.